Showing 1741-1750 of 2652 results for "".
- Bausch + Lomb’s ONE by ONE and Biotrue Eye Care Recycling Programs Recognized As Sustainability Service of the Year Award Winnerhttps://modernod.com/news/bausch-lombs-one-by-one-and-biotrue-eye-care-recycling-programs-recognized-as-sustainability-service-of-the-year-award-winner/2481839/Bausch + Lomb announced that its ONE by ONE and Biotrue Eye Care Recycling programs have been recognized as 2023 Sustainability Award winners by Business Intelligence Group in the “Sustainability Service of the Year” category. “Millions of people wear co
- Ciliatech Presents Preliminary 1-Year Study Results on Treating Open and Narrow Angle Glaucoma with CIDhttps://modernod.com/news/ciliatech-presents-preliminary-1-year-study-results-on-treating-open-and-narrow-angle-glaucoma-with-cid/2481814/Ciliatech announced it will present at the Ophthalmology Futures Symposium the preliminary results of a 1-year study of its clinical trial, SAFARI III, involving both open and narrow angle glaucoma patients. Preliminary outcomes show an excellent performance and safety profile, wit
- SightGlass Vision Reports 4-Year Clinical Trial Outcomes for Myopia Control DOT Spectacle Lenseshttps://modernod.com/news/sightglass-vision-reports-4-year-clinical-trial-outcomes-for-myopia-control-dot-spectacle-lenses/2481810/SightGlass Vision reported positive 4-year outcomes from its pivotal CYPRESS study extension, which is evaluating the myopia control performance of the company’s Diffusion Optics Technology (DOT 0.2) spectacle lenses. The lenses use thousands of light scattering el
- Regeneron Presents 2-Year PULSAR Trial Results for Aflibercept 8 MG in Wet AMDhttps://modernod.com/news/regeneron-presents-2-year-pulsar-trial-results-for-aflibercept-8-mg-in-wet-amd/2481772/Regeneron announced positive, 2-year (96 weeks), topline data from the pivotal PULSAR trial investigating aflibercept 8 mg in patients with wet age-related macular degeneration (AMD). During the trial, aflibercept 8 mg patients were initially randomized to either 12- or 16-week dosing interv
- Optometry and Vision Science Names New Editor-in-Chiefhttps://modernod.com/news/optometry-and-vision-science-announces-new-editor-in-chief/2481744/The American Academy of Optometry (AAO) announced that David Elliott, PhD, FCOptom, FAAO, is the new editor-in-chief of Optometry and Vision Science (OVS). Mr. Elliott succeeds Michael Twa, OD, PhD, FAAO, who is stepping down from the role after 7 years.
- Ciliatech Presents 2-Year Postoperative Results on New Cilio-Scleral Surgical Approach for Treating Glaucomahttps://modernod.com/news/ciliatech-presents-2-year-postoperative-results-on-new-cilio-scleral-surgical-approach-for-treating-glaucoma/2481698/Ciliatech announced it will present the preliminary results of the second 2-year postoperative clinical trial (SAFARI II) on its Cilia-scleral Interposition Device (CID) during the World Glaucoma Congress, taking place this week. Ciliatech will present results showing sta
- Two-Year Results for Aflibercept 8 mg from PHOTON Trial Demonstrate Durable Vision Gains at Extended Dosing Intervals in DMEhttps://modernod.com/news/two-year-results-for-aflibercept-8-mg-from-photon-trial-demonstrate-durable-vision-gains-at-extended-dosing-intervals-in-dme/2481696/Regeneron released on Tuesday topline, 2-year (96 weeks) data for aflibercept 8 mg from the PHOTON trial in patients with diabetic macular edema (DME). During the trial, aflibercept 8 mg patients were initially randomized to either 12- or 16-week dosing intervals (after three initial monthly
- The International Agency for the Prevention of Blindness (IAPB) Welcomes Over 300 International Delegates to Singaporehttps://modernod.com/news/the-international-agency-for-the-prevention-of-blindness-iapb-welcomes-over-300-international-delegates-to-singapore/2481690/The International Agency for the Prevention of Blindness (IAPB) has welcomed more than 300 delegates to Singapore for its "2030 IN SIGHT LIVE" event. Hosted in partnership with the Singapore Eye Research Institute (SERI), the event gathers experts and thought leaders from eye
- iSTAR Medical to Present New 3-Year STAR-GLOBAL Data at World Glaucoma Congresshttps://modernod.com/news/istar-medical-to-present-new-3-year-star-global-data-at-world-glaucoma-congress/2481683/iSTAR Medical announced that it will be hosting a symposium where it will present 3-year interim data from the STAR-GLOBAL trial and will also be running a dry lab at its booth at the 10th World Glaucoma Congress (WGC) taking place in Rome, Italy from June 28 to July 1, 2023.
- Yuyu Pharma Announces Topline Results from the ICECAP Phase 1/2 Trial of YP-P10 in Dry Eye Diseasehttps://modernod.com/news/yuyu-pharma-announces-topline-results-from-the-icecap-phase-12-trial-of-yp-p10-in-dry-eye-disease/2481651/Yuyu Pharma announced topline results from the ICECAP phase 1/2 trial of YP-P10 in patients with dry eye disease. ICECAP was the first human, signal-seeking, phase 1/2 trial evaluating the safety and efficacy of YP-P10 over 12 weeks (85 days) of treatment in subjects with dry eye disease, ac